↓ Skip to main content

Dove Medical Press

Article Metrics

Emerging drugs for partial-onset epilepsy: a review of brivaracetam

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
5 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
21 Mendeley
Title
Emerging drugs for partial-onset epilepsy: a review of brivaracetam
Published in
Therapeutics and Clinical Risk Management, May 2016
DOI 10.2147/tcrm.s90127
Pubmed ID
Authors

Shu Chuen Li, Lan Gao

Abstract

There are more than 12 new antiepileptic drugs approved in the last 2 decades. Even with these newer agents, seizure remission is still unachievable in around 30% of patients with partial-onset seizures (POS). Brivaracetam (BRV) is chemically related to levetiracetam (LEV) and possesses a strong binding affinity for the synaptic vesicle protein 2A tenfold above that of LEV, and other possible modes of antiepileptic actions. BRV is now under Phase III development for POS, but data from one Phase III trial also suggested its potential efficacy for primary generalized seizures. The purpose of this review is to provide updated information on the mechanisms of action of the available antiepileptic drugs, with a focus on BRV to assess its pharmacology, pharmacokinetics, clinical efficacy, safety, and tolerability in patients with uncontrolled POS. To date, six Phase IIb and III clinical trials have been performed to investigate the efficacy, safety, and tolerability of BRV as an adjunctive treatment for patients with POS. Generally, BRV was well tolerated and did not show significant difference in safety profile, compared to placebo. The efficacy outcomes of BRV, although not consistent across trials, did indicate that BRV was a promising add-on therapy for patients with POS. In conclusion, the many favorable attributes of BRV, like its high oral efficacy, good tolerability, dosing regimen, and minimal drug interaction, make it a promising antiepileptic therapy for patients with uncontrolled partial-onset epilepsy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 29%
Researcher 3 14%
Student > Bachelor 3 14%
Unspecified 2 10%
Student > Ph. D. Student 2 10%
Other 5 24%
Readers by discipline Count As %
Medicine and Dentistry 5 24%
Unspecified 4 19%
Pharmacology, Toxicology and Pharmaceutical Science 3 14%
Social Sciences 3 14%
Psychology 3 14%
Other 3 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2016.
All research outputs
#6,488,581
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#357
of 922 outputs
Outputs of similar age
#98,931
of 264,013 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#10
of 53 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,013 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.